Your browser is no longer supported. Please, upgrade your browser.
ZFGN Zafgen, Inc. monthly Stock Chart
ZFGN [NASD]
Zafgen, Inc.
Index- P/E- EPS (ttm)-2.59 Insider Own0.40% Shs Outstand26.43M Perf Week1.20%
Market Cap111.80M Forward P/E- EPS next Y-2.18 Insider Trans23.33% Shs Float26.01M Perf Month29.75%
Income-70.60M PEG- EPS next Q-0.49 Inst Own69.50% Short Float2.94% Perf Quarter19.15%
Sales- P/S- EPS this Y7.50% Inst Trans0.04% Short Ratio2.21 Perf Half Y-36.68%
Book/sh4.76 P/B0.89 EPS next Y2.70% ROA-43.00% Target Price5.25 Perf Year-35.42%
Cash/sh5.25 P/C0.81 EPS next 5Y- ROE-47.40% 52W Range2.89 - 12.18 Perf YTD33.02%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-65.27% Beta-
Dividend %- Quick Ratio12.50 Sales past 5Y- Gross Margin- 52W Low46.37% ATR0.25
Employees47 Current Ratio12.50 Sales Q/Q- Oper. Margin- RSI (14)66.37 Volatility9.35% 6.80%
OptionableYes Debt/Eq0.03 EPS Q/Q26.70% Profit Margin- Rel Volume1.40 Prev Close4.09
ShortableYes LT Debt/Eq0.01 EarningsFeb 08 AMC Payout- Avg Volume346.40K Price4.23
Recom2.80 SMA2022.17% SMA5023.70% SMA200-7.37% Volume484,380 Change3.42%
Jan-06-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jul-20-16Downgrade FBR Capital Outperform → Mkt Perform $20 → $5
Mar-10-16Reiterated RBC Capital Mkts Outperform $21 → $19
Jan-21-16Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $21
Jan-21-16Upgrade FBR Capital Mkt Perform → Outperform $9 → $20
Dec-03-15Downgrade Sun Trust Rbsn Humphrey Buy → Neutral
Dec-03-15Downgrade Leerink Partners Outperform → Mkt Perform
Dec-02-15Downgrade RBC Capital Mkts Outperform → Sector Perform $20 → $7
Nov-13-15Reiterated Canaccord Genuity Buy $53 → $30
Oct-19-15Reiterated RBC Capital Mkts Outperform $46 → $20
Oct-19-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-16-15Downgrade FBR Capital Outperform → Mkt Perform $48 → $16
Oct-15-15Reiterated RBC Capital Mkts Outperform $58 → $46
Oct-15-15Reiterated FBR Capital Outperform $60 → $48
Jun-17-15Initiated Sun Trust Rbsn Humphrey Buy $47
May-13-15Reiterated Canaccord Genuity Buy $58 → $53
Jan-23-15Initiated RBC Capital Mkts Outperform $53
Aug-13-14Initiated Canaccord Genuity Buy $36
Jan-06-17 07:17AM  Zafgen upgraded by JMP Securities +24.78%
Dec-12-16 11:44PM  How Zafgen Inc (ZFGN) Stacks Up Against Its Peers at Insider Monkey
Dec-01-16 08:47AM  Zafgen, Inc. :ZFGN-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-17-16 01:04PM  ZAFGEN, INC. Financials
Nov-09-16 05:57PM  Zafgen reports 3Q loss +8.20%
04:15PM  ZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Zafgen Reports Third Quarter 2016 Financial Results GlobeNewswire
Sep-20-16 12:17PM  Zafgen, Inc. :ZFGN-US: Earnings Analysis: Q2, 2016 By the Numbers : September 20, 2016 +6.37%
07:00AM  Zafgen Initiates Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of ZGN-1061 GlobeNewswire
Aug-05-16 06:07AM  ZAFGEN, INC. Files SEC form 10-Q, Quarterly Report +5.57%
Aug-04-16 06:43PM  Zafgen reports 2Q loss
04:13PM  ZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Zafgen Reports Second Quarter 2016 Financial Results GlobeNewswire
Aug-03-16 05:00PM  Zafgen to Present at Canaccord Genuitys 36th Annual Growth Conference GlobeNewswire
09:30AM  Zacks.com featured highlights: Danaos, Telecom Italia, Fibria Celulose, Goodyear Tire & Rubber and Zafgen
Jul-29-16 09:53AM  Zafgen (ZFGN) Is in Oversold Territory: What's Next?
Jul-21-16 04:04PM  Biotech Firm Zafgen in Thursdays 52-Week Low Club at 24/7 Wall St. -7.72%
09:30AM  The Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen
Jul-20-16 04:04PM  2 Staggering Biotechs Join Wednesdays 52-Week Low Club at 24/7 Wall St. -52.00%
03:50PM  Why Valeant, Progenics, Ryerson, Zafgen and TerraForm Are On The Move Today at Insider Monkey
03:36PM  Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug
10:45AM  Why Zafgen (ZFGN) Stock Is Tanking Today
09:44AM  Zafgen Halts Development of Beloranib, to Cut Jobs by ~34%
Jul-19-16 05:35PM  Zafgen shares drop more than 40% as drug focus shifted at MarketWatch
05:22PM  ZAFGEN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and Ex
04:47PM  Zafgen to scrap obesity drug, cut jobs
04:05PM  Zafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061 GlobeNewswire
Jul-01-16 04:32PM  ZAFGEN, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-13-16 05:45PM  Zafgen (ZFGN) Presents Favorable New Data on Beloranib
09:36AM  Zafgen up 6% after weight loss drug has positive late-stage trial results at MarketWatch
Jun-11-16 11:00AM  Zafgen Presents New Data from the Phase 2b Clinical Trial Evaluating Beloranib in Severe Obesity Complicated by Type 2 Diabetes at the American Diabetes Association's 76th Scientific Sessions GlobeNewswire
Jun-06-16 02:28PM  Zafgen, Inc. :ZFGN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016
May-11-16 11:20AM  Hopes rise for FDA approval of Zafgens fat-busting drug among analysts, investors at bizjournals.com
May-10-16 06:14PM  Zafgen reports 1Q loss
04:30PM  ZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Zafgen Reports First Quarter 2016 Financial Results GlobeNewswire
May-03-16 04:05PM  Zafgen to Host Conference Call to Discuss First Quarter 2016 Financial Results GlobeNewswire
Apr-06-16 01:53PM  Edited Transcript of ZFGN earnings conference call or presentation 9-Mar-16 9:30pm GMT
Apr-04-16 02:47PM  Why These Five Stocks Are Trending on Monday at Insider Monkey +8.66%
11:42AM  Penny Stocks To Buy: Traders Are Considering Stocks On This List, Monday 4/4/2016 Accesswire
10:21AM  Zafgen (ZFGN) Stock Surges on Positive Obesity Drug Trial at TheStreet
08:42AM  Biotech Firm Receives Key Patent Notice Accesswire
Apr-03-16 01:15PM  Zafgen Presents New Data from the Phase 3 bestPWS Study Evaluating Beloranib in Prader-Willi Syndrome at ENDO 2016 GlobeNewswire
Mar-28-16 04:22PM  Zafgen to Present Data from bestPWS Study of Beloranib in Prader-Willi Syndrome at ENDO 2016 at noodls
04:05PM  Zafgen to Present Data from bestPWS Study of Beloranib in Prader-Willi Syndrome at ENDO 2016 GlobeNewswire
Mar-24-16 07:15AM  Why investors arent really buying Kerrisdales short attack on Sage Therapeutics at bizjournals.com
Mar-15-16 04:15PM  ZAFGEN, INC. Files SEC form 10-K, Annual Report
Mar-10-16 03:16PM  Zafgen (ZFGN) Stock Sinks on Q4 Loss at TheStreet -9.78%
Mar-09-16 04:55PM  Zafgen reports 4Q loss
04:20PM  ZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Zafgen Reports Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
Mar-08-16 05:02PM  ZAFGEN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial State -8.20%
07:00AM  Zafgen Adds Thomas O. Daniel, M.D. to Its Board of Directors GlobeNewswire
Mar-02-16 04:00PM  Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire +9.19%
Mar-01-16 07:00AM  Zafgen to Present at the Cowen & Company 36th Annual Health Care Conference GlobeNewswire
Feb-29-16 07:00AM  Zafgen Joins NORD in Raising Awareness of Rare Disease Day GlobeNewswire -8.21%
Feb-20-16 10:15AM  The Top 4 Biopharma Movers of the Past Week at 24/7 Wall St.
Feb-19-16 04:05PM  Thromboembolic Risks Linger For Zafgen's Beloranib, Says SunTrust
03:20PM  Zafgen Up, Beloranib Hits Phase IIb Primary Efficacy Endpoint
Feb-18-16 04:25PM  Die Hard starts winning again
12:05PM  Zafgen's drug may help one of the leading causes of death, but safety issues remain at bizjournals.com
08:50AM  Zafgen Soars on Positive Phase 2 Results at 24/7 Wall St.
08:48AM  Here's Why Zafgen Gained 20% Thursday Morning
07:01AM  ZAFGEN, INC. Files SEC form 8-K, Other Events
06:48AM  Zafgen's obesity drug succeeds in mid-stage trial Reuters
06:30AM  Zafgen's Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint GlobeNewswire
Feb-17-16 11:52AM  This firm is now one of just two Mass. biotechs trading up this year at bizjournals.com
Feb-16-16 04:05PM  Zafgen to Participate in Upcoming Investor Conferences GlobeNewswire +10.20%
Feb-12-16 02:07PM  Billionaire Singer Lifts Stake in Cabelas Inc. (CAB), Deerfield Bets on Beloranib, Plus Two Other Moves at Insider Monkey
Feb-11-16 10:13AM  5 Stocks Under $10 Set to Soar at TheStreet
Feb-02-16 07:00AM  Zafgen to Present at Upcoming Investor Conferences GlobeNewswire
Feb-01-16 08:00AM  Biotech Sector Report; Potential Rebound for These Four Biotech Securities Accesswire
Jan-25-16 01:31PM  Some cheap biotech stocks that could be buyout targets, RBC says at MarketWatch -10.52%
12:51PM  Why Zafgen (ZFGN) Stock Is Falling Today at TheStreet
12:25PM  Why Zafgen Inc's Stock Is in the Red Today at Motley Fool
11:02AM  Zafgen stock tumbles after hedge fund reveals short position Reuters
09:36AM  Kerrisdale Short Zafgen, Says Beloranib Has 'No Reasonable Chance' Of FDA Approval And Recent Bullishness Is 'Misplaced'
Jan-21-16 03:30PM  Zafgen Soars on Positive Phase III Efficacy Data on Beloranib -9.26%
12:09PM  Zafgen (ZFGN) Stock Upgraded at RBC Capital at TheStreet
11:51AM  Zafgen Doubles: What Do The Experts Think?
08:55AM  Top Analyst Upgrades and Downgrades: GE, 3M, Shopify, SunPower, Zafgen, CIT, Ericsson, Honeywell and Many More at 24/7 Wall St.
Jan-20-16 05:29PM  ZAFGEN, INC. Files SEC form 8-K, Other Events +78.65%
03:42PM  What is Happening to These Stocks on Wednesday? at Insider Monkey
03:00PM  Zafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug Results at TheStreet
02:06PM  [$$] Zafgen Completes Beloranib Trial, Will Address Clinical Hold at The Wall Street Journal
11:35AM  4 Stocks That Are Trading Higher In The Face of the Down Market Today Accesswire
11:08AM  Why Shares of Zafgen Skyrocketed Today at Motley Fool
08:45AM  Why Zafgen Is Trading Higher By 40%
08:40AM  Has a Zafgen Turnaround Begun? at 24/7 Wall St.
06:21AM  Zafgen says obesity drug succeeds in late-stage study Reuters
06:00AM  Zafgen's Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints GlobeNewswire
06:00AM  Zafgen Surges as New Drug Findings May Help Restart FDA Review at Bloomberg
Jan-19-16 11:50AM  Local gainers, losers from JP Morgan conference at bizjournals.com
Jan-13-16 06:24AM  3 Biotech Stocks Under $10 to Trade for Big Breakouts at TheStreet -5.98%
Jan-02-16 10:15AM  4 Top FDA Decisions Expected in Q1 at 24/7 Wall St.
Dec-18-15 07:01PM  INVESTOR ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Zafgen, Inc. and a Lead Plaintiff Deadline of December 21, 2015 - ZFGN GlobeNewswire
Dec-17-15 10:00AM  Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Zafgen, Inc. and Lead Plaintiff Deadline - December 21, 2015 Accesswire
Dec-15-15 09:48AM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of Zafgen, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of December 21, 2015 Business Wire
Dec-14-15 05:46PM  Upcoming Deadline Alert: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Zafgen, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit Business Wire
11:36AM  The Wagner Firm Announces the Filing of a Securities Class Action on Behalf of Zafgen, Inc. Investors Business Wire
Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate is the Beloranib, an injection, which is in Phase III clinical trials for the treatment of obesity and hyperphagia in patients with Prader-Willi syndrome; that has completed Phase II clinical trials to treat hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which has completed Phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor that is in pre-clinical studies for the treatment of nonalcoholic steatohepatitis and abdominal obesity, as well as other second-generation MetAP2 inhibitors to treat severe obesity. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Heller Frances KDirectorDec 19Buy3.2310,00032,29030,000Dec 20 05:02 PM
Heller Frances KDirectorNov 15Buy3.5410,00035,43420,000Nov 17 05:00 PM